Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 901 to 915 of 2042 results for guidelines

  1. Into practice

    Tools and resources to help you implement guidance and quality standards at work.

  2. Into practice

    Tools and resources to help you implement guidance and quality standards at work.

  3. Promoting independence through intermediate care

    Promoting independence through intermediate care - a quick guide for staff delivering intermediate care services.

  4. Good practice guidance – Interim process statement (PMG3)

    Good practice guidance – Interim process statement

  5. Improving young people's experiences in transition to and from inpatient mental health settings

    A quick guide for mental health practitioners supporting young people transitioning to and from inpatient mental health settings

  6. Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

    Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.

  7. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.

  8. Migraine prophylaxis: flunarizine (ESUOM33)

    Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making

  9. Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry (MIB113)

    NICE has developed a medtech innovation briefing (MIB) on the Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry .

  10. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.

  11. Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

    Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

  12. Dapagliflozin for treating chronic kidney disease (TA775)

    Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.

  13. Diabetes: statins for secondary prevention of CVD (IND184)

    This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM163

  14. Pregnancy and neonates: breastfeeding 48 hours (IND20)

    This indicator covers the percentage of mothers who give their babies breast milk in the first 48 hours after delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG33

  15. PLGF-based testing to help diagnose suspected preterm pre-eclampsia (DG49)

    Evidence-based recommendations on placental growth factor (PLGF)-based testing to help diagnose suspected preterm pre-eclampsia. The tests are: DELFIA Xpress PLGF 1 2 3, DELFIA Xpress sFlt 1/PLGF 1 2 3 ratio, Elecsys immunoassay sFlt 1/PLGF ratio, Triage PLGF Test